Opioid overdose

Using ‘trip killers’ to cut short bad drug trips is potentially dangerous

Retrieved on: 
Wednesday, February 14, 2024

As interest in psychedelics has grown, so has interest in ways to end a bad trip.

Key Points: 
  • As interest in psychedelics has grown, so has interest in ways to end a bad trip.
  • Recent research reveals that people are giving potentially dangerous advice on social media on how to stop a trip that is less than pleasurable.
  • One of the earliest descriptions of a psychedelic experience in western literature can be found in Aldous Huxley’s 1953 book The Doors of Perception.
  • Research shows that if someone is in a bad mood or depressed then they are more likely to have a bad trip, as are people who take too high a dose.

Trip killers

  • Few clinical studies have examined trip killers, but one has found that ketanserin – a drug used to treat high blood pressure – reverses the psychedelic effects of LSD.
  • A recent article in the Emergency Medical Journal analysed posts on Reddit about trip killers.
  • Trip killers were discussed most often for LSD (235 posts), magic mushrooms (143 posts) and MDMA (21 posts).

Receptor blocking

  • To kill a trip then, one simply has to give the drug user another drug that blocks (rather than activates) the 5-HT2A receptor.
  • Many prescription drugs can do this and they tend to be antipsychotic drugs.
  • Quetiapine from the list above is one popular example, while another antipsychotic, olanzapine, was mentioned in 14 posts in that study.
  • Similarly, the atypical antidepressants trazodone and mirtazapine also block the 5-HT2A receptor.


Colin Davidson has previously received funding from the National Institute on Drug Abuse (NIH, USA) and the European Community for projects related to stimulant drug abuse and novel psychoactive compounds respectively. He is currently a paid consultant with the Defence Science Technology Laboratory (MOD) working on new psychoactive compounds.

First Shipment of RiVive(TM) Brings Life-saving Over-The-Counter Nalxone Nasal Spray One Step Closer to Those Who Need It Most

Retrieved on: 
Monday, December 18, 2023

Remedy Alliance has also made an additional purchase of about 28,000 twin packs of RiVive.

Key Points: 
  • Remedy Alliance has also made an additional purchase of about 28,000 twin packs of RiVive.
  • By funding organizations like HRT or Remedy Alliance, you can help to prevent further deaths from opioid overdoses."
  • If the person does not respond after 2-3 minutes, additional doses of RiVive may be given until the person wakes up.
  • RiVive will be exclusively available in twin packs containing two single-dose devices, initially to community organizations and governments.

Increasing Wages Will Lead to Healthier Work and Healthier Workers

Retrieved on: 
Wednesday, November 29, 2023

LOS ANGELES, Nov. 29, 2023 /PRNewswire/ -- The Healthy Work Campaign applauds California for leading the way in 2023 to ensure fair, living wages for healthcare and fast-food workers.

Key Points: 
  • LOS ANGELES, Nov. 29, 2023 /PRNewswire/ -- The Healthy Work Campaign applauds California for leading the way in 2023 to ensure fair, living wages for healthcare and fast-food workers.
  • California has recognized that, due to wage stagnation and inflation, the living standard of low-income workers has been in decline for many years.
  • The Healthy Work Campaign has reported previously about the contribution of poor working conditions (including low wages) to the health of workers, especially those without a 4-year college degree, which includes fast-food workers and some healthcare support workers .
  • The Healthy Work Campaign urges other states to follow California's lead, to improve economic justice and the health of low-income workers throughout the U.S.

Optum Rx Takes Additional Steps to Lower the Cost of Insulin

Retrieved on: 
Thursday, November 9, 2023

In all, Optum Rx will shift eight products, including all short- and rapid-acting insulins, to tier one, or “preferred” status on standard formularies.

Key Points: 
  • In all, Optum Rx will shift eight products, including all short- and rapid-acting insulins, to tier one, or “preferred” status on standard formularies.
  • In total, 170 unique medications are part of the Optum Rx Critical Drug Affordability program that includes a recommended cost share of $35 or less for consumers.
  • Today more than 70% of people who use Optum Rx already pay less than $35 per month on insulin.
  • Effective Jan. 1, 2024, thanks to the latest actions by Optum Rx, 98% of all Optum Rx consumers will have access to insulin for $35 or less per month.

Orexo Q3 2023 Interim Report

Retrieved on: 
Thursday, November 2, 2023

UPPSALA, Sweden, Nov. 2, 2023 /PRNewswire/ --

Key Points: 
  • ›     EBITDA of SEK -9.5 m (-32.4), EBITDA excluding costs for legal processes and external non-­repeating ­­clinical trials, SEK 13.3 m (14.3)
    ›     The first patent issued in the US for OX640, epinephrine rescue medication for allergic reactions
    ›     OX124, high-dose rescue medication for opioid overdose, refiled with the FDA
    ›     The MODIA® study didn't meet the ­primary end-points, but showed high rates of treatment ­response in both study arms, with no adverse events associated with the use of MODIA
    ›     Robin Evers elected as board member at the Extraordinary General Meeting.
  • He replaces ­Henrik ­Kjaer ­Hansen who has announced he will resign.
  • Kjaer Hansen, has instead been appointed ­c­­hairman of the Nomination Committee, representing Novo Holdings A/S

Orexo Q3 2023 Interim Report

Retrieved on: 
Thursday, November 2, 2023

UPPSALA, Sweden, Nov. 2, 2023 /PRNewswire/ --

Key Points: 
  • ›     EBITDA of SEK -9.5 m (-32.4), EBITDA excluding costs for legal processes and external non-­repeating ­­clinical trials, SEK 13.3 m (14.3)
    ›     The first patent issued in the US for OX640, epinephrine rescue medication for allergic reactions
    ›     OX124, high-dose rescue medication for opioid overdose, refiled with the FDA
    ›     The MODIA® study didn't meet the ­primary end-points, but showed high rates of treatment ­response in both study arms, with no adverse events associated with the use of MODIA
    ›     Robin Evers elected as board member at the Extraordinary General Meeting.
  • He replaces ­Henrik ­Kjaer ­Hansen who has announced he will resign.
  • Kjaer Hansen, has instead been appointed ­c­­hairman of the Nomination Committee, representing Novo Holdings A/S

National Fire Sprinkler Association Supports National Fire Service Initiatives

Retrieved on: 
Wednesday, October 11, 2023

Linthicum Heights, MD, Oct. 11, 2023 (GLOBE NEWSWIRE) -- The National Fire Sprinkler Association is proud to support and partner with other national fire service organizations in support of national initiatives.

Key Points: 
  • Linthicum Heights, MD, Oct. 11, 2023 (GLOBE NEWSWIRE) -- The National Fire Sprinkler Association is proud to support and partner with other national fire service organizations in support of national initiatives.
  • “We are happy to support and be involved in so many positive national fire initiatives, this week’s Summit on Fire Prevention and Control brought together national leaders to share about so many important issues affecting us all,” stated Shane Ray, NFSA President and Congressional Fire Service Institute board member.
  • WHO:   This event is hosted by the Congressional Fire Services Institute, International Association of Fire Chiefs, International Association of Fire Fighters, National Fallen Firefighters Foundation, National Fire Protection Association, and National Volunteer Fire Council.
  • Even while they protect their communities from an ever-increasing range of hazards, firefighters face physical and mental health challenges due to their service.

National Safety Council Launches New Program to Combat Soaring Workplace Overdose Deaths

Retrieved on: 
Monday, September 18, 2023

WASHINGTON, Sept. 18, 2023 /PRNewswire/ -- Overdoses are the leading cause of unintentional death in the United States and can happen anywhere anytime, workplaces included. Deaths on the job from drug overdoses have increased 536% since 2011. To combat this alarming rise from the workplace to anyplace, the National Safety Council is launching a new workplace safety program, Respond Ready Workplace, designed to increase awareness of the need for naloxone in workplaces and ensure people are trained to use it.

Key Points: 
  • To combat this alarming rise from the workplace to anyplace, the National Safety Council is launching a new workplace safety program, Respond Ready Workplace , designed to increase awareness of the need for naloxone in workplaces and ensure people are trained to use it.
  • "The Respond Ready Workplace program is a pivotal step forward in reducing overdose deaths and protecting workers everywhere," said Lorraine Martin, president and CEO of the National Safety Council.
  • Key highlights of the Respond Ready Workplace initiative include:
    Advocacy and Education: Most employers do not understand the tragic data on the increasing fatalities in the workplace.
  • To learn more about the Respond Ready Workplace program and how organizations can get involved, please visit nsc.org/respondready .

Orexo submits New Drug Application to FDA for OX124, a high-dose rescue medication for opioid overdose

Retrieved on: 
Monday, September 18, 2023

), (STO: ORX) (OTCQX: ORXOY), today announces the submission of the New Drug Application (NDA) to the US Food and Drug Administration (FDA) for OX124, a high-dose rescue medication for opioid overdose with nasal delivery.

Key Points: 
  • ), (STO: ORX) (OTCQX: ORXOY), today announces the submission of the New Drug Application (NDA) to the US Food and Drug Administration (FDA) for OX124, a high-dose rescue medication for opioid overdose with nasal delivery.
  • OX124, is based on Orexo´s world-class drug delivery platform amorphOX® and is designed to reverse the effects of the most powerful synthetic opioids, such as fentanyl.
  • [2] The great majority, 76 percent, refers to opioid overdoses, and of these 91 percent involved synthetic opioids.
  • Me and my team look forward to giving broad access to this important and differentiated medication."

Orexo submits New Drug Application to FDA for OX124, a high-dose rescue medication for opioid overdose

Retrieved on: 
Monday, September 18, 2023

), (STO: ORX) (OTCQX: ORXOY), today announces the submission of the New Drug Application (NDA) to the US Food and Drug Administration (FDA) for OX124, a high-dose rescue medication for opioid overdose with nasal delivery.

Key Points: 
  • ), (STO: ORX) (OTCQX: ORXOY), today announces the submission of the New Drug Application (NDA) to the US Food and Drug Administration (FDA) for OX124, a high-dose rescue medication for opioid overdose with nasal delivery.
  • OX124, is based on Orexo´s world-class drug delivery platform amorphOX® and is designed to reverse the effects of the most powerful synthetic opioids, such as fentanyl.
  • [2] The great majority, 76 percent, refers to opioid overdoses, and of these 91 percent involved synthetic opioids.
  • Me and my team look forward to giving broad access to this important and differentiated medication."